Researchers at The Ottawa Hospital are playing a lead role in 15 new projects awarded more than $8.4 million from the Canadian Institutes of Health Research (CIHR).

These projects will advance science and improve health in areas such as pregnancy, mental health, neuromuscular disease, cancer, venous thrombosis, infectious disease, knowledge translation, diagnostic tests, lung disease and stroke.

“These research projects will help us provide the best care possible for our patients and community, while advancing science and improving health on a global scale,” said Dr. Duncan Stewart.

The Ottawa Hospital Research Institute had a success rate of 38 percent in this competition compared to the national average of 35 percent. Over the last three years, The Ottawa Hospital has held an average rank of #4 among hospitals for CIHR funding.

The new grants include:

The maternal endothelium in gestational diabetes mellitus - $860,625

• Principal Investigator(s): Burger, Dylan; Shah, Baiju R; Dolinsky, Vernon W

Infant and child health outcomes following SARS-CoV-2 infection in pregnancy - $100,000

• Principal Investigator(s): El-Chaar, Darine; Brophy, Jason C; Hawken, Steven
• Co-Investigator(s): Walker, Mark C; Fell, Deshayne B; Dunn, Sandra I; Corsi, Daniel J; Pham-Huy, Anne; Cameron, D.William; Cook, Jocelynn L; Muldoon, Katherine A; Murphy, Malia S; Van Lieshout, Ryan J Kharrat, Ashraf; Carsley, Sarah; Ducharme, Robin

Development of a suicide prevention strategy for Public Safety Personnel - $650,251

• Principal Investigator(s): Hatcher, Simon
• Co-Investigator(s): Carleton, R. Nicholas, Ricciardelli, Rose, Kennedy, Sidney H, Dmetrichuk, Jennifer, Devlin, Julie H, Mishara, Brian L, Cramm, Heidi, Shields, Norman M, Heber, Alexandra, DuBois, Denise MacDermid, Joy C, Genest, Christine

Extra-neuronal contribution to spinal muscular atrophy disease pathogenesis - $818,550

• Principal Investigator(s): Kothary, Rashmi K

PREVENT GU: Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial - $424,575

• Principal Investigator(s): Lavallée, Luke T; Breau, Rodney H; Bossé, Dominick; Carrier, Marc
• Co-Investigator(s): Cagiannos, Ilias; Mallick, Ranjeeta; Fergusson, Dean A; Wang, Tzu-Fei; Reaume, Martin N; McAlpine, Kristen; Winquist, Eric; Hotte, Sebastien; Lazo-Langner, Alejandro; Ikesaka, Rick T Lalani, Aly-Khan; Morash, Chris G; Sridhar, Srikala S; Ong, Michael; Canil, Christina M; Huynh, Melissa

A Randomized Controlled Non-Inferiority Trial to Assess the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Adult Inflammatory Bowel Disease - $650,249

• Principal Investigator(s): Murthy, Sanjay K; Fergusson, Dean A
• Co-Investigator(s): Jairath, Vipul; Bernstein, Charles N; Riddell, Robert H; Nguyen, Geoffrey C

Epigenetic Regulation of the Adenovirus Genome- $696,150

• Principal Investigator(s): Parks, Robin J

Evaluating and Improving a National Learning Network- $619,650

• Principal Investigator(s): Seely, Andrew J; Brehaut, Jamie C; Taljaard, Monica
• Co-Investigator(s): Ferri, Lorenzo; Finley, Christian J; Kidane, Biniam; Moffatt-Bruce, Susan D; Presseau, Justin; Ramsay, Timothy O; Thavorn, Kednapa; Villeneuve, Patrick J

AMSTAR-DTA: A Measurement Tool to Assess Systematic Reviews of Diagnostic Test Accuracy Studies -$100,000

• Principal Investigator(s): Shea, Beverley J
• Co-Investigator(s): Henry, David A; Moher, David; Welch, Vivian A; Hamel, Candyce; Reeves, Barnaby C; McInnes, Matthew; Tugwell, Peter S; Wells, George A

Reducing Gastrointestinal Bleeding with Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism (RADIANT) Pilot Randomized Trial - $543,149

• Principal Investigator(s): Siegal, Deborah M; Delluc, Aurelien
• Co-Investigator(s): Rodger, Marc A; Skeith, Leslie; Abdulrehman, Jameel; Gross, Peter L Wang, Tzu-Fei; Carrier, Marc; Xu, Yan; Castellucci, Lana; Barkun, Alan N; Forbes, Nauzer; Ramsay, Timothy O

Imbalance Between Vascular Injury and Repair in PAH- $868, 275

• Principal Investigator(s): Stewart, Duncan J

Therapeutic potential of stem cells in lung injury -$100,000

• Principal Investigator(s): Thébaud, Bernard

Increasing anti-tumoral responses to ovarian cancer using engineered viruses- $906,525

• Principal Investigator(s): Vanderhyden, Barbara C
• Co-Investigator(s): Auer, Rebecca Ann C; Rodriguez, Galaxia M; Cook, David P

ACT WHEN Randomized Controlled Trial - $1,575,899

• Principal Investigator(s): Menon, Bijoy K; Almekhlafi, Mohammed A; Dowlatshahi, Dariush
• Co-Investigator(s): Alhabli, Ibrahim; Ben-Israel, David; Buck, Brian H; Catanese, Luciana; Demchuk, Andrew M; Ganesh, Aravind; Hill, Michael D; Joundi, Raed; Katsanos, Aristeidis; Kim, Beom Joon; Poppe, Alexandre Y; Sajobi, Tolulope T; Shankar, Jai J; Singh, Nishita; Swartz, Richard; Thavorn, Kednapa; Tkach, Aleks
• Note: this grant is administered at the University of Calgary

• Principal Investigator(s): Emond, Marcel; Malo, Christian; Mercier, Eric; Yadav, Krishan
• Co-Investigator(s): BALEN, Frederic; Batomen Kuimi, Brice Lionel; BENHAMED, Axel; Berthelot, Simon; Bérubé, Mélanie; Blanchard, Pierre-Gilles; Brousseau, Audrey-Anne; Clark, Greg; D'Astous, Myreille; de Wit, Kerstin; Eagles, Debra; Lessard, Justine; Stiell, Ian G; Vaillancourt, Samuel
• Note: this grant is administered at Université Laval

These projects are supported by core resources for research at The Ottawa Hospital, such as the Ottawa Methods Centre.

The Ottawa Hospital is a leading academic health, research and learning hospital proudly affiliated with the University of Ottawa and supported by The Ottawa Hospital Foundation. 

Media Contact 

Jenn Ganton

613-614-5253

jganton@ohri.ca